Blog
RSS FeedPosted by Michael Wonder on 03 Apr 2026
Sevabertinib approved to treat adults with HER2 positive lung cancer that has spread or cannot be removed by surgery
2 April 2026 - The MHRA has approved sevabertinib (Hyrnuo) to treat adults with advanced non-small cell lung cancer with ...
Posted by Michael Wonder on 03 Apr 2026
NHS patients and British businesses to benefit from historic changes to medicines access following pharmaceutical partnership with US
2 April 2026 - New partnership accelerates NHS patients' access to new medicines and will see UK benefit from greater life ...
Posted by Michael Wonder on 03 Apr 2026
Changes to NICE’s cost effectiveness thresholds take effect
2 April 2026 - NICE has implemented new measures to evaluate the cost effectiveness of medicines, following a policy change that ...
Posted by Michael Wonder on 03 Apr 2026
MHRA-NICE pathway opens for business – everything you need to know to get started
1 April 2026 - Today marks a significant milestone for patients, the NHS and the pharmaceutical industry. From 1 April 2026, ...
Posted by Michael Wonder on 01 Apr 2026
Injection for more than a million people to help prevent heart attacks and strokes recommended
1 April 2026 - People who have had a heart attack, stroke, or serious circulation problem in their legs, and who ...
Posted by Michael Wonder on 30 Mar 2026
Eli Lilly pushes for NHS drug price increases in return for its UK investment
30 March 2026 - US pharmaceutical group ‘optimistic’ about reaching deal with British Government. ...
Posted by Michael Wonder on 20 Mar 2026
NHS spending watchdog to review evidence on Alzheimer’s treatments
20 March 2026 - England’s drugs costs watchdog is to look again at whether new treatments for Alzheimer’s disease should ...
Posted by Michael Wonder on 18 Mar 2026
Patients to get new medicines up to six months sooner
17 March 2026 - Patients in England are set to receive some new medicines 3 to 6 months earlier under a ...
Posted by Michael Wonder on 13 Mar 2026
MHRA approves deuruxolitinib (Leqselvi) to treat severe alopecia areata in adults
12 March 2026 - The MHRA has approved deuruxolitinib (Leqselvi) to treat severe alopecia areata in adults. ...
Posted by Michael Wonder on 12 Mar 2026
500,000 eligible to benefit from new non-hormonal treatment for hot flushes caused by menopause
11 March 2026 - A new treatment option for menopausal hot flushes and night sweats can be used in the NHS ...
Posted by Michael Wonder on 25 Feb 2026
MHRA approves imlunestrant tosylate (Inluryo) - a new treatment for breast cancer
24 February 2026 - The MHRA has today approved imlunestrant tosylate (Inluriyo), a new treatment for adult patients with a ...
Posted by Michael Wonder on 24 Feb 2026
Brensocatib licensed as the first medicine specifically designed to treat non-cystic fibrosis bronchiectasis in patients 12 years and older
23 February 2026 - The Medicines and Healthcare products Regulatory Agency (MHRA) has granted a marketing authorisation for the medicine brensocatib ...
Posted by Michael Wonder on 21 Feb 2026
MHRA approves zanidatamab (Ziihera) for the treatment of biliary tract cancer
19 February 2026 - Zanidatamab is used when the cancer cannot be removed by surgery and has spread to nearby tissues ...
Posted by Michael Wonder on 18 Feb 2026
NICE recommends first ever disease modifying treatment for ARG1 deficiency
17 February 2026 - NICE has recommended the first disease modifying treatment for arginase 1 deficiency (ARG1-D), an ultra-rare, inherited and ...
Posted by Michael Wonder on 28 Jan 2026
MHRA takes over Chair of International Access Consortium for 2026
26 January 2026 - The MHRA has formally begun its year as chair of the Access Consortium for 2026, marking ...